These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2002 related articles for article (PubMed ID: 29306329)

  • 1. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
    Namani A; Matiur Rahaman M; Chen M; Tang X
    BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex components by multiple genetic mechanisms: Association with poor prognosis in head and neck cancer.
    Martinez VD; Vucic EA; Thu KL; Pikor LA; Lam S; Lam WL
    Head Neck; 2015 May; 37(5):727-34. PubMed ID: 24596130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
    Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
    J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas.
    Jin X; Zheng Y; Chen Z; Wang F; Bi G; Li M; Liang J; Sui Q; Bian Y; Hu Z; Qiao Y; Xu S
    Cancer Med; 2021 Dec; 10(23):8673-8692. PubMed ID: 34617407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulation and Epigenetic Reprogramming of NRF2 Signaling Axis Promote Acquisition of Cisplatin Resistance and Metastasis in Head and Neck Squamous Cell Carcinoma.
    Osman AA; Arslan E; Bartels M; Michikawa C; Lindemann A; Tomczak K; Yu W; Sandulache V; Ma W; Shen L; Wang J; Singh AK; Frederick MJ; Spencer ND; Kovacs J; Heffernan T; Symmans WF; Rai K; Myers JN
    Clin Cancer Res; 2023 Apr; 29(7):1344-1359. PubMed ID: 36689560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrative investigation on significant mutations and their down-stream pathways in lung squamous cell carcinoma reveals CUL3/KEAP1/NRF2 relevant subtypes.
    Liu Z; Deng M; Wu L; Zhang S
    Mol Med; 2020 May; 26(1):48. PubMed ID: 32434476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation.
    Tang YC; Hsiao JR; Jiang SS; Chang JY; Chu PY; Liu KJ; Fang HL; Lin LM; Chen HH; Huang YW; Chen YT; Tsai FY; Lin SF; Chuang YJ; Kuo CC
    Theranostics; 2021; 11(11):5232-5247. PubMed ID: 33859744
    [No Abstract]   [Full Text] [Related]  

  • 8. Genetic alterations of Keap1 confers chemotherapeutic resistance through functional activation of Nrf2 and Notch pathway in head and neck squamous cell carcinoma.
    Islam SS; Qassem K; Islam S; Parag RR; Rahman MZ; Farhat WA; Yeger H; Aboussekhra A; Karakas B; Noman ASM
    Cell Death Dis; 2022 Aug; 13(8):696. PubMed ID: 35945195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Potential Biomarkers and Survival Analysis for Head and Neck Squamous Cell Carcinoma Using Bioinformatics Strategy: A Study Based on TCGA and GEO Datasets.
    Shen Y; Liu J; Zhang L; Dong S; Zhang J; Liu Y; Zhou H; Dong W
    Biomed Res Int; 2019; 2019():7376034. PubMed ID: 31485443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma.
    Ramesh PS; Bovilla VR; Swamy VH; Manoli NN; Dasegowda KB; Siddegowda SM; Chandrashekarappa S; Somasundara VM; Kabekkodu SP; Rajesh R; Devegowda D; Thimmulappa RK
    Free Radic Biol Med; 2023 Aug; 205():234-243. PubMed ID: 37328018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma.
    Madhukar G; Subbarao N
    J Biomol Struct Dyn; 2024; 42(4):1875-1900. PubMed ID: 37160694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent concerted genetic mechanisms disrupt multiple components of the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in thyroid cancer.
    Martinez VD; Vucic EA; Pikor LA; Thu KL; Hubaux R; Lam WL
    Mol Cancer; 2013 Oct; 12(1):124. PubMed ID: 24138990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma.
    Cescon DW; She D; Sakashita S; Zhu CQ; Pintilie M; Shepherd FA; Tsao MS
    Clin Cancer Res; 2015 Jun; 21(11):2499-505. PubMed ID: 25739673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of SELENBP1 enhances oral squamous cell carcinoma chemoresistance through KEAP1-NRF2 signaling.
    Zeng H; Zhao X; Tang C
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):223-233. PubMed ID: 33907880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower DSC1 expression is related to the poor differentiation and prognosis of head and neck squamous cell carcinoma (HNSCC).
    Wang Y; Chen C; Wang X; Jin F; Liu Y; Liu H; Li T; Fu J
    J Cancer Res Clin Oncol; 2016 Dec; 142(12):2461-2468. PubMed ID: 27601166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prognostic mRNA expression signature of four 16q24.3 genes in radio(chemo)therapy-treated head and neck squamous cell carcinoma (HNSCC).
    Wintergerst L; Selmansberger M; Maihoefer C; Schüttrumpf L; Walch A; Wilke C; Pitea A; Woischke C; Baumeister P; Kirchner T; Belka C; Ganswindt U; Zitzelsberger H; Unger K; Hess J
    Mol Oncol; 2018 Dec; 12(12):2085-2101. PubMed ID: 30259648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSTM3 deficiency impedes DNA mismatch repair to promote gastric tumorigenesis via CAND1/NRF2-KEAP1 signaling.
    Chen T; Jinlin D; Wang F; Yuan Z; Xue J; Lu T; Huang W; Liu Y; Zhang Y
    Cancer Lett; 2022 Jul; 538():215692. PubMed ID: 35487311
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Akdemir B; Nakajima Y; Inazawa J; Inoue J
    Mol Cancer Res; 2017 Nov; 15(11):1570-1578. PubMed ID: 28760781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KEAP1/NRF2 signaling pathway mutations in cervical cancer.
    Chu XY; Li ZJ; Zheng ZW; Tao YL; Zou FX; Yang XF
    Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4458-4466. PubMed ID: 30058679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 101.